June 16, 2010 New
Relypsa Initiates Open-Label Phase 2 Clinical Study of RLY5016 for the Management of Hyperkalemia
June 16, 2010 New
Relypsa Appoints Claire J. Lockey Vice President, Regulatory Affairs
October 7, 2009
Relypsa Initiates Phase 2b Clinical Trial of RLY5016 for the Prevention of Hyperkalemia in Heart Failure Patients
January 9, 2008
Relypsa appoints Ronald A. Krasnow Senior Vice President, Intellectual Property and Chief Patent Counsel.
October 29, 2007
Relypsa formed with $33 Million Series A Funding to discover and develop polymeric drugs.
|
